Tecentriq is now the first immunotherapy indicated for dMMR colon cancer treatment specifically, which is often linked to a higher risk of progression after surgery.

Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone Nearly one in three patients ...

Young Americans with colorectal cancer are most likely to have the disease in their rectums, experts believe. A new report from the American Cancer Society provides further evidence for an alarming ...

Yogurt, which contains live strains of bacteria, is thought to protect against many types of diseases, with some reports indicating it could reduce the risk of colorectal cancer. A new study led by ...